BGBIO.OL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 1370 min ago

@ NOK0.147

Wydano: 30 bal. 2024 @ 15:16

Zwrot: -1.09%

Poprzedni sygnał: bal. 30 - 12:11

Poprzedni sygnał: Sprzedaż

Zwrot: -0.81 %

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 17:25):

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
Dzisiejszy wolumen	28.91M
Średni wolumen	42.95M
Kapitalizacja rynkowa	566.76M
EPS	NOK0 ( 2024-02-15 )
Następna data zysków	( NOK-0.0200 ) 2024-05-23
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.260
ATR14	NOK0.00700 (4.83%)

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: 0.00 (neutral)

Signal:(0) Neutral

BerGenBio ASA Korelacja

10 Najbardziej pozytywne korelacje
PLT.OL	0.937
ELIMP.OL	0.935
KMCP.OL	0.931
TRVX.OL	0.925
ELABS.OL	0.908
ABG.OL	0.895
AKER.OL	0.893
VOW.OL	0.892
SADG.OL	0.891
EFUEL.OL	0.884

10 Najbardziej negatywne korelacje
AYFIE.OL	-0.95
ATEA.OL	-0.929
TECH.OL	-0.886
ELK.OL	-0.885
BAKKA.OL	-0.882
BWO.OL	-0.877
PEXIP.OL	-0.871
BOUV.OL	-0.865
GOD.OL	-0.864
SMOP.OL	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BerGenBio ASA Korelacja - Waluta/Towar

0.00
( neutral )

BerGenBio ASA Finanse

Annual	2022
Przychody:	NOK389 000
Zysk brutto:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2022
Przychody:	NOK389 000
Zysk brutto:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2021
Przychody:	NOK774 000
Zysk brutto:	NOK0.00 (0.00 %)
EPS:	NOK-3.52

FY	2020
Przychody:	NOK601 000
Zysk brutto:	NOK0.00 (0.00 %)
EPS:	NOK-3.43

Financial Reports:

No articles found.

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.